Clinical Utility of Body Weight Monitoring During Cisplatin-based Chemotherapy.

BACKGROUND/AIM: Acute kidney injury (AKI) is one of the most frequent adverse effects induced by cisplatin (CDDP). One clinical indicator of CDDP-induced AKI is urine output, which reflects water balance; however, urine collection can expose healthcare workers to anticancer drugs. An alternative monitoring approach for CDDP-induced AKI is weight-based assessment of fluid balance. Although previous studies have evaluated the relationship between body weight change and CDDP-induced AKI, few have evaluated the amount of water ingested. Therefore, we evaluated water intake, urine output, and body weight changes in patients treated with CDDP to determine the utility of weight monitoring as an indicator of fluid balance during CDDP-based chemotherapy.

PATIENTS AND

METHODS

We evaluated 15 patients who received CDDP-vinorelbine as postoperative adjuvant chemotherapy for non-small cell lung cancer from March to December 2019. Patients recorded their oral fluid intake, and body weight changes were evaluated on days 2-4 relative to baseline on day 1.

RESULTS

No cases of CDDP-induced AKI occurred. Compared with day 1, urine output decreased on day 2 but recovered on day 3. Body weight fluctuations were highest (+3.6 kg) on day 3 and started decreasing on day 4. Serum creatinine and estimated glomerular filtration rate did not differ significantly pre- and post-chemotherapy. A positive correlation was observed between water balance and next-morning weight change (r=0.68).

CONCLUSION

Weight monitoring may reduce healthcare workers' exposure to anticancer agents while serving as a practical indicator of fluid balance during CDDP-based chemotherapy.